Life science associations are calling for ATMPs to be exempted from the strict EU GMO rules, as their different legal interpretations in EU member states are delaying applications for multicentre clinical trials.
APEIRON Biologics’ recombinant ACE2 APN01 has been selected to participate in the US ACTIV study. ACTIV is aimed to speed up development of the best COVID-19 meds.
Danish Novo Holdings A/S has led an oversubscribed US$125m Series C into the cancer antibody specialist Hummingbird Bioscience.
BD will build a €165m manufacturing facility in Zaragoza, Spain to support the growth of its pre-filled drug delivery business.
German government has launched a €300m programme designed to bring clinically tested COVID-19 treatments to the patient’s bedside.
AMSilk GmbH has closed a Series C financing at €29m to accelerate and expand commercialisation of its microbially produced silk fibres.
Immunoglobin G antibodies (IgG) produced in response to the SARS-CoV-2 spike protein appear to play a role in how COVID-19 can turn more severe in some cases.
International life sciences investment group Abingworth has closed a new clinical co-development fund at US$582m.
The Biden administration has announced it will support the WHO proposal to temporarily waive intellectual property rights for COVID-19 vaccines to speed up vaccination.
Topical ophthalmic therapies developer Oculis S.A. has closed a US$57m Series C financing to push development of its pipeline.